唐尧生物科技
济南华维医药科技有限公司
Huawei Pharmaceutical Co. Ltd.
  • 公司概况
  • 济南华维医药科技有限公司(原上海华潍医药正式迁入山东济南药谷)是中国一流的新药筛选专业CRO公司,本公司专注于提供1.1类新药在分子水平、细胞水平、动物水平上的药效学筛选服务。

          济南华维在分子水平上可以提供的筛选服务包括,聚合ADP核糖聚合酶,酪氨酸激酶,蛋白酪氨酸磷酸酶(PTP),丝/苏氨酸激酶,组蛋白去乙酰化酶,组蛋白去甲基化酶,组蛋白甲基转移酶,DNA甲基转移酶,热休克蛋白,基质金属蛋白酶,抑制微管蛋白聚集及解聚酶,蛋白酶体,拓扑异构酶,二肽基肽酶,去乙酰化酶,过氧化物酶体增殖剂激活受体,其他与代谢相关的酶,细胞毒T淋巴细胞相关抗原4,磷酸二酯酶,磷脂酶A,调节血脂,抗病毒,抗凝血,抗高血压,溴结构域蛋白,组织蛋白酶,凋亡相关,泛素相关,β淀粉样蛋白,乙酰胆碱酯酶等,共计500余种新药靶点,涉及的疾病种类为抗肿瘤,抗糖尿病,抗炎症,免疫调节,抗病毒,心脑血管病,血液系统疾病,阿尔茨海默病等。

          济南华维在细胞水平上可以针对十几条主要的信号通路进行抑制剂的筛选,包括 cAMP/CRE/CREB通路, Hedgehog通路, JAK/STAT通路,JNK通路,. MEK/ERK通路,NF-KB通路, Notch通路, Nrf2 antioxidant通路, PI3K/AKT通路, Wnt/ catenin通路,RAR Nuclear receptor通路,TGF/SMAD通路。我公司建有较齐全的细胞库,可以针对各种正常细胞及肿瘤细胞开展细胞增殖抑制实验,细胞周期阻滞实验,细胞凋亡实验,细胞迁移实验,细胞转染及RNA干扰实验,细胞集落形成实验,针对耐药细胞株的增殖抑制实验,细胞水平的P糖蛋白底物抑制剂检测,DNA Ladder实验,基因过表达及基因沉默实验,细胞骨架免疫荧光实验,蛋白免疫印迹Western blot 实验,大鼠动脉环实验,HUVEC的管腔形成实验,活细胞水平HDAC抑制的测试,PARP的增敏细胞实验。

    济南华维拥有符合国际标准的动物饲养管理设施和现代化的功能实验室。动物饲养设施可饲养裸鼠、小鼠、大鼠、豚鼠、兔等实验动物;技术人员熟练掌握静脉注射、肌肉注射、皮下注射、腹腔注射、口服给药、经皮给药、吸入及鼻腔喷雾、滴眼及视网膜下注射等给药方式及动静脉等多种取血方式。可以对抗肿瘤药物,抗糖尿病药物及抗炎症药物,通过相应的实验动物模型进行药效学评价。

           济南华维的核心团队均具有博士学位,在大型制药企业或CRO公司从事过多年的药物筛选与开发经验,曾成功完成近百个IND的研究与申报,涵盖药物研发的多数热点领域。公司还拥有强大的顾问团队,他们均来自于药物研发的一线,能够精确把握最新的药物筛选与开发的热点技术和趋势,他们分别就职于国内外著名的科研院所、监管评审机构以及世界前十大药厂。本公司可以为客户提供最热门药物靶点相关的新药快速筛选的相关CRO服务,可以极大的提高客户进行新药筛选的实验效率,节约实验成本。        

           济南华维将以最先进的理念和最高的质量服务于客户,以缩短客户研发周期和减少客户研发成本为服务宗旨,在生物技术领域提供一如既往高品质的产品与服务,期待与您的合作!








  • 更多信息>>
  • 联系我们
  • 电 话:   15821697315 微信号: 15821697315 QQ: 1621015150
  • 0531-58990387
  • 传 真:   021-64828900
  • E-mail
  • 1621015150@qq.com
  • QQ
  • 欢迎在线咨询
  • 欧洲药监局批准首个基因治疗药物Glybera
  • Regulatory watch: Pioneering gene therapy on brink of approval

    Alexandra Flemming

    After two and a half years and three prior negative opinions, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has now backed the approval of alipogene tiparvovec (Glybera, UniQure), an adeno-associated virus (AAV) vector encoding lipoprotein lipase (LPL), for the treatment of LPL deficiency in patients with severe or multiple pancreatitis attacks. Approval by the European Commission, which is anticipated within the next 3 months, would make Glybera the first gene therapy to be approved outside China.

    LPL deficiency is a rare autosomal recessive single gene deficiency, affecting about 1–2 people per million. It causes the build-up of lipoproteins in the gut wall following a meal and is associated with a number of complications, such as pancreatitis, which can be life-threatening. Currently, there are no drugs to treat this condition.

    “LPL is a great model for gene therapy since it is a recessive disease in which easily measured biomarkers can be used to assess the efficiency and stability of transgene expression,” explains James Wilson, Professor of Pathology at the University of Pennsylvania, USA, who developed the AAV1 vector used in Glybera.

    However, the rarity of the disease made clinical trials for this therapy especially challenging. Safety is also a key concern for gene therapy approaches in general — particularly with regards to potential immune reactions to the vector and insertional mutagenesis.

    “Over 10 years, Glybera was tested in two observational studies and three interventional clinical studies, first in the Netherlands and then in Canada,” says Daniel Gaudet, Professor at the University of Montreal, Canada, who led the clinical trials. “It was well tolerated by the majority of the 27 patients in the interventional studies, and local adverse reactions were found to be due to local LPL activity rather than anti-AAV immune responses,” he adds. Barrie Carter, Past-President of the American Society for Gene and Cell Therapy, points out that AAV vectors, overall, have an impressive safety record. “The most notable feature about these vectors is the fact that their genomes persist in the nucleus as episomes, leading to very long-term expression of the transgene, with extremely low integration rates into the nuclear DNA,” he says.

    A substantial number of other AAV-based products are in early clinical development, targeting other tissues or organs such as retina, liver and brain. UniQure is currently running five other gene therapy programmes, the most advanced of which involves an AAV vector encoding factor IX that has completed a Phase I/II trial for the treatment of haemophilia B.

    Wilson thinks that the approval of Glybera will be huge in terms of encouraging further investment in gene therapy products. Gaudet adds that although the approval of Glybera will have limited impact clinically, it will have a substantial impact from a regulatory perspective: “It demonstrates that it is possible for a gene-based medication to be approved despite all the barriers, which include the complexity of the treatment, as well as many technical, clinical, social and ethical questions.”

    (From NATURE REVIEWS DRUG DISCOVERY

  • 关闭  打印 登出时间 2012-09-01
  • 地址:山东省济南市高新区港兴三路济南药谷1号楼A座2508
  • 电话:15821697315 微信号: 15821697315 QQ: 1621015150 / 0531-58990387   传真:021-64828900
  • Powered by TANG 3.6 Copyright @ 2012 - 2015 唐尧生物